

Raymed Labs Ltd.

Manufacturers of Allopathic Medicines

CIN: L24111UP1992PLC014240

REGISTERED OFFICE,

703, ASTER 7, SUPERTech EMERALD COURT, SECTOR-93A, NOIDA-201304 (U.P.)

e-mail : raymedlabs@rediffmail.com website : www.raymedlab.com

Tel. 0120-2426900, 9412700300

13th November 2017

The Head-Listing Compliance

BSE Limited

Phiroze Jeejeebhoy Towers

Dalal Street

Mumbai 400001

Scrip Code: 531207

Subject: Outcome of Board Meeting pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/Madam:

We would like to inform that the Board of Directors in their meeting held today, i.e. Monday, November 13, 2017, (commenced at 12:30 P.M. and concluded at 05:30 P.M.) have considered and approved inter alia following:

1. Unaudited Standalone Financial Results as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the Quarter and half year ended September 30, 2017. **(Copy Enclosed)**
2. Took on record, the Limited Review Report on Financial Results for the Quarter and half year ended September 30, 2017 as placed by the Statutory Auditor of the Company. **(Copy Enclosed)**
3. Took note of Statement of Investor Complaints/Grievances under Regulation 13(3) of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 for the Quarter ended September 30, 2017.

Kindly take the above information on your records.

Sincerely,

For Raymed Labs Limited

Ajai Goyal

Ajai Goyal

Whole Time Director

DIN: 02636418



**Add: 703 Aster 7, Supertech Emerald Court
Sector 93A, Noida 201304**

Life is Preciousand Raymed cares

Raymed Labs Limited

Regd. Office: 703 Aster 7, Supertech Emerald Court, Sector 93A, Noida - 201304, Uttar Pradesh

CIN: L24111UP1992PLC014240

E-Mail: raymedlabs@rediffmail.com, Website: www.raymedlab.com, Tel: 0120-2426900, 9412700300

Statement of Standalone Unaudited Financial Results for the Quarter and Half Year ended September 30, 2017

Amount (In Lakhs)

Particulars	Three months ended			Six months ended	
	Quarter ended 30-09-2017	Preceding 3 month ended 30-06-2017	Corresponding 3 month ended 30-09-2016	Year to date figures for the Current year period ended on 30-09-2017	Year to date figures for the previous year period ended on 30-09-2016
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)
I. Revenue from Operations	-	-	-	-	-
II. Other Income	0.30	0.30	0.30	0.60	0.60
III. Total Income (I + II)	0.30	0.30	0.30	0.60	0.60
IV. Expenses					
Cost of Material Consumed	-	-	-	-	-
Purchases of Stock-in-trade	-	-	-	-	-
Changes in inventories of finished goods, Work-in-progress and stock-in-trade	-	-	-	-	-
Excise Duty	-	-	-	-	-
Employee Benefits Expenses	0.38	0.23	0.23	0.61	0.81
Finance Costs	-	-	-	-	-
Depreciation and amortisation expenses	0.17	0.17	0.22	0.34	0.44
Other Expenses	0.85	0.41	0.57	1.26	0.98
Total Expenses (IV)	1.40	0.81	1.02	2.21	2.23
V. Profit/(Loss) before exceptional items and tax (III-IV)	-1.10	-0.51	-0.72	-1.61	-1.63
VI. Exceptional items	-	2.88	-	2.88	2.29
VII. Profit/(Loss) before tax (V-VI)	-1.10	-3.39	-0.72	-4.49	-3.92
VIII. Tax Expense					
(1) Current tax	-	-	-	-	-
(2) Deferred tax	-	-	-	-	-
IX. Profit/(Loss) for the period (VII-VIII)	-1.10	-3.39	-0.72	-4.49	-3.92
X. Other Comprehensive Income					
(A) (i) Items that will not be reclassified to profit or loss	-	-	-	-	-
(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-
(B) (i) Items that will be classified to profit or loss	-	-	-	-	-
(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-
XI. Total Comprehensive Income / (loss) for the period (XIII+XIV)	-1.10	-3.39	-0.72	-4.49	-3.92
XII. Paid-up Equity share capital (Face Value of Rs. 10/- per share)	427.35	427.35	427.35	427.35	427.35
XIII. Earnings per equity share of Rs. 10/- per share (not annualised):					
(1) Basic	-0.026	-0.079	-0.017	-0.105	-0.092
(2) Diluted	-0.026	-0.079	-0.017	-0.105	-0.092

Notes:

(1) The above results have been reviewed by Audit Committee and taken on record by the Board of Directors at its Meeting held on 13th day of November 2017. The Statutory Auditors have carried out a Limited Review of the above results.

(2) The above results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (IND AS), prescribed under section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable.

(3) The statement does not include Ind AS compliant results for previous year ended March 31, 2017 as the same is not mandatory as per SEBI circular dated July 5, 2016

(4) The IND AS compliant corresponding figures for the quarter and six months ended 30th September, 2016 have not been subjected to limited review or audit. However, the Company's management has exercised necessary due diligence to ensure that such financial results provide a true and


(5) The figures for the previous period have been regrouped/reclassified, wherever necessary, to make them comparable.

(6) As the Company's business activity falls within a single segment, therefore disclosure requirements of the Accounting Standard (AS) 17 "Segment Reporting" prescribed by Companies (Accounting Standards) Rules 2006 are not applicable.

(7) Reconciliation of Net Profit / (Loss) as previously reported under GAAP and IND AS for the period as reported above has been given in the table below:

Particulars	(Rs. In Lakhs)	
	Quarter ended	Six Month ended
Reconciliation of Net Profit / (Loss) as previously reported in GAAP and IND AS		
Profit/Loss after tax as per Previous GAAP	(0.72)	(3.92)
Profit/Loss after tax as reported under Ind AS	(0.72)	(3.92)
Other Comprehensive Income	0.00	0.00
Total Comprehensive Income / (loss) as reported under Ind AS	(0.72)	(3.92)

For Raymed Labs Limited



Ajai Goyal

Whole Time Director

DIN: 02636418

Add: 703 Aster 7, Supertech Emerald Court

Sector 93A, Noida 201304 (U.P)

Date: 13.11.2017

Place: Noida



Raymed Labs Limited

Regd. Office: 703 Aster 7, Supertech Emerald Court, Sector 93A, Noida - 201304, Uttar Pradesh

CIN: L24111UP1992PLC014240

E-Mail: raymedlabs@rediffmail.com, Website: www.raymedlab.com, Tel: 0120-2426900,
9412700300

Unaudited Standalone Statement of Assets and Liabilities


(Amount in Lakhs)

S. No.	Particulars	Standalone
		As on 30.09.2017
		Unaudited
A	ASSETS	
1	Non-current assets	
	a. Property, plant and equipment	18.60
	b. Capital work-in-progress	-
	c. Investment property	-
	d. Goodwill	-
	e. Other intangible assets	-
	f. Intangible assets under development	-
	g. Biological assets other than bearer plants	-
	h. Financial Assets	-
	i. Investments	-
	ii. Trade receivables	-
	iii. Loans	-
	iv. Others	-
	i. Deferred tax assets (net)	-
	j. Other non-current assets	-
	Sub-total non-current assets	18.60
2	Current assets	
	a. Inventories	-
	b. Financial Assets	
	i. Investments	-
	ii. Trade receivables	2.49
	iii. Cash and cash equivalents	0.02
	iv. Bank balance other than cash and cash equivalents	0.03
	v. Loans	6.00
	vi. Others	0.45
	c. Current tax assets (net)	-
	d. Other current assets	-
	Sub-total current assets	8.99
	TOTAL ASSETS	27.59

B	EQUITY AND LIABILITIES	
1	Equity	
	a. Equity Share Capital	427.35
	b. Other equity	-613.32
	Sub-total equity	-185.97
2	Non-current liabilities	
	a. Financial liabilities	
	(i) Borrowings	-
	(ii) Trade payables	-
	(iii) Other non-current financial liabilities	-
	b. Provisions	-
	c. Deferred tax liabilities (net)	-
	d. Other non-current liabilities	-
	Sub-total Non current liabilities	-
3	Current liabilities	
	a. Financial liabilities	
	(i) Borrowings	198.80
	(ii) Trade payables	4.32
	(iii) Other financial liabilities	5.00
	b. Other current liabilities	5.44
	c. Provisions	-
	d. Current tax liabilities (Net)	-
	Total current liabilities	213.56
	TOTAL LIABILITIES	213.56
	TOTAL EQUITY AND LIABILITIES	27.59

Place : Noida
Dated: 13.11.2017

By the order of the Board
For Raymed Labs Limited



Ajai Goyal
Whole Time Director
DIN 02636418

Add: 703 Aster 7, Supertech
Emerald Court, Sector 93A,
Noida – 201304 (U.P)



A. Kay. Mehra & Co.

CHARTERED ACCOUNTANTS

114 (Basement), Mall Road, Kingsway Camp, Delhi-110009

Tel No. : 011-42461274, 9891295255, 9818708294

E-mail : akmca1969@gmail.com Website : www.akmca.in

INDEPENDENT AUDITOR'S LIMITED REVIEW REPORT FOR QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2017


To
The Board of Directors
Raymed Labs Limited
703, Aster 7, Supertech Emerald Court,
Sector 93A, Noida- 201304

1. We have reviewed the accompanying statement of unaudited financial results ("The Statement") of **Raymed Labs Limited** ("The Company") for the quarter and six months ended 30th September, 2017 and the statement of assets and liabilities on that date ("The Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.

Attention is drawn to the fact that the amounts for the corresponding quarter and half year ended September 30, 2016, including the reconciliation of net profit or loss under Ind AS of the said quarter and half year with net profit or loss reported under previous GAAP, as included in the Statement have not been subject to limited review or audit. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement prepared in accordance with applicable accounting standards, as notified under the Companies (Indian Accounting Standards) Rules, 2015 as specified in Section 133 of the Companies Act, 2013 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016 and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: New Delhi
Date: November 13, 2017

For A Kay Mehra & Co.
Chartered Accountants
M.F.R.N. 050004C

A Deepak Suneja
Partner
(Membership No. 501957)